Xencor (XNCR) Upgraded at BidaskClub

BidaskClub upgraded shares of Xencor (NASDAQ:XNCR) from a strong sell rating to a sell rating in a report released on Wednesday morning.

A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research restated a sell rating on shares of Xencor in a report on Saturday, January 13th. Cantor Fitzgerald began coverage on shares of Xencor in a report on Wednesday, November 29th. They issued an overweight rating and a $33.00 price objective for the company. Piper Jaffray Companies restated a buy rating and issued a $35.00 price objective on shares of Xencor in a report on Sunday, November 12th. ValuEngine lowered shares of Xencor from a hold rating to a sell rating in a report on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 target price on shares of Xencor and gave the stock a buy rating in a research note on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $30.80.

Get Xencor alerts:

Shares of Xencor (NASDAQ XNCR) opened at $23.40 on Wednesday. The firm has a market cap of $1,100.00, a P/E ratio of -23.17 and a beta of 2.09. Xencor has a 1-year low of $18.55 and a 1-year high of $28.64.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative return on equity of 15.26% and a negative net margin of 148.29%. equities analysts forecast that Xencor will post -1.1 EPS for the current year.

In other news, major shareholder John S. Stafford III bought 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were bought at an average cost of $19.58 per share, with a total value of $979,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder John S. Stafford III bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, October 27th. The stock was purchased at an average cost of $19.81 per share, for a total transaction of $2,971,500.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 253,882 shares of company stock worth $5,033,630. 4.14% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of XNCR. Great West Life Assurance Co. Can increased its position in Xencor by 158.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 4,005 shares during the period. Legal & General Group Plc increased its position in Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 385 shares during the period. Principal Financial Group Inc. purchased a new position in Xencor during the 3rd quarter valued at $201,000. Citadel Advisors LLC purchased a new position in Xencor during the 2nd quarter valued at $224,000. Finally, Voya Investment Management LLC increased its position in Xencor by 25.4% during the 2nd quarter. Voya Investment Management LLC now owns 16,793 shares of the biopharmaceutical company’s stock valued at $355,000 after purchasing an additional 3,405 shares during the period. 77.50% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Xencor (XNCR) Upgraded at BidaskClub” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/xencor-xncr-upgraded-at-bidaskclub/1823675.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.